Farnesyl transferase inhibitors in the treatment of breast cancer

Expert Opinion on Investigational Drugs

Volumn 12, Issue 3, 2003, Pages 413-421

  Kelland, Lloyd ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast; Cancer; Farnesyl transferase; Inhibitors

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ALKYLATING AGENT; ANASTROZOLE; ANTHRACYCLINE; ANTIESTROGEN; ANTIMETABOLITE; AROMATASE INHIBITOR; CARBON; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; L 778123; LETROZOLE; LONAFARNIB; ONCOPROTEIN; PLACEBO; PRENYLAMINE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RECEPTOR BLOCKING AGENT; TAMOXIFEN; TAXANE DERIVATIVE; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; METABOLIC DISORDER; NEUROTOXICITY; ONCOGENE C ERB; PANCREAS CANCER; PARESTHESIA; POLYDIPSIA; PRENYLATION; PROTEIN FUNCTION; RASH; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; BREAST NEOPLASMS; CLINICAL TRIALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; IMIDAZOLES; PIPERIDINES; PYRIDINES; QUINOLONES; RAS PROTEINS;

EID: 0037340739     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.3.413     Document Type: Review

References (56)

1. SMITH IE: New drugs for breast cancer. Lancet (2002) 360:790-792.
2. SLAMON DJ, CLARK GM, WONG SG, LEVIN WJ, ULLRICH A, MCGUIRE WL: Human breast cancer: correlation with relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235:177-182.
3. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
4. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
5. JOENSUU H, ROBERTS PJ, SARLOMO-RIKALA M et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. (2001) 344:1052-1056.
6. BARBACID M: Ras genes. Ann. Rev. Biochem. (1987) 56:779-827.
7. BOS JL: Pas oncogenes in human cancer: A review. Cancer Res. (1989) 49:4682-4689.
8. HANCOCK JF, MAGEE AI, CHILDS JE, MARSHALL CJ: All ras proteins are polyisoprenylated but only some are palmitoylated. Cell (1989) 57:1167-1177.
9. KOHL NE, OMER CA, CONNER MW et al.: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Medicine (1995) 1:792-797.
10. CLARK GJ, DER CJ: Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res. Treat. (1995) 35:133-144.
11. NORGAARD P, LAW B, JOSEPH H et al.: Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res. (1999) 5:35-42.
12. SEPP-LORENZINO L, MA Z, RANDS E, KOHL NE, GIBBS JB, ROSEN NA: A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. (1995) 55:5301-5309.
13. END DW, SMETS G, TODD A et al.: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. (2001) 61:131-137.
14. COX AD, DER CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply ras? Biochim. Biophys. Acta (1997) 1333:F51-F71.
15. ASHAR HR, JAMES L, GRAY K et al.: Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem. (2000) 275:30451-30457.
16. ROWELL CA, KOWALCZYK JJ, LEWIS MD, GARCIA AM: Direct demonstration of geranylgeranylation and farnesylation of ki-ras in vivo. J. Biol. Chem. (1997) 272:14093-14097.
17. WHYTE DB, KIRSCHMEIER P, HOCKENBERRY TNJ et al.: K- and N-ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. (1997) 272:14459-14464.
18. PRENDERGAST GC: Actin' up: RhoB in cancer and apoptosis. Nat. Rev. Cancer (2001) 1:162-168.
19. DU W, LEBOWITZ PF, PRENDERGAST GC: Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. (1999) 19:1831-1840.
20. LEBOWITZ PF, CASEY PJ, PRENDERGAST GC, THISSEN JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of Rho B. J. Biol. Chem. (1997) 272:15591-15594.
21. VAN GOLEN KL, BAO L, DIVITO MM, PRENDERGAST GC, MERAJVER SD: Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol. Cancer Ther. (2002) 1:575-583.
22. JIANG K, COPPOLA D, CRESPO NC et al.: The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol. (2000) 20:139-148.
23. KELLAND LR, SMITH V, VALENTI M et al.: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin. Cancer Res. (2001) 7:3544-3550.
24. ZUJEWSKI J, HORAK ID, BOL CJ, et al.: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. (2000) 18:927-941.
25. KARP JE, LANCET JE, KAUFMANN SH et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase I clinical-laboratory correlative trial. Blood (2001) 97:3361-3369.
26. PUNT CJ, VAN MAANEN L, BOL CJ, SEIFERT WF, WAGENER DJ: Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs (2001) 12:193-197.
27. CRUL M, DE KLERK G, SWART M et al.: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. (2002) 20:2726-2735.
28. LANCET JE, ROSENBLATT J, KARP JE: Farnesyltransferase inhibitors and myeloid malignancies: Phase I evidence of Zarnestra activity in high-risk leukemias. Semin. Hematol. (2002) 39:31-35.
29. JOHNSTON SRD, HICKISH T, HOUSTON S, ELLIS PA, HOWES AJ, THIBAULT A: Efficacy and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:35a (Abstract).
30. HAROUSSEAU J-L, STONE R, THOMAS X et al.: Interim results from a Phase II study of R115777 (Zarnestra) in patients with relapsed and refractory acute myelogenous leukemia. Proc. Am. Soc. Clin. Oncol. (2002) 21:265a (Abstract).
31. CORTES JE, ALBITAR M, THOMAS D et al.: Efficacy of the farnesyl transferase inhibitor, ZARNESTRATM (R115777), in chronic myeloid leukemia and other other hematological malignancies. Blood (2002) (E-pub ahead of print).
32. GOTLIB J, DUGAN K, KATAMNENI U et al.: Phase I/II study of farnesyltransferase inhibitor R115777 (Zarnestra) in patients with myeloproliferative disorders (MPDs): preliminary results. Proc. Am. Soc. Clin. Oncol. (2002) 21:4a (Abstract).
33. CLOUGHESY TF, KUHN J, WEN P et al.: Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol. (2002) 21:80a (Abstract).
34. HEYMACH JV, DE PORRE PM, DEVORE RF et al.: Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. (2002) 21:139a (Abstract).
35. ADJEI AA, MAUER A, MARKS R et al.: A Phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:290a (Abstract).
36. MACDONALD JS, CHANSKY K, WHITEHEAD R, WADE J, GIGUERE J, ABBRUZZESE JL: A Phase II study of the farnesyl transferase inhibitor R115777 in pancreatic cancer. A southwest oncology group (SWOG) study. Proc. Am. Soc. Clin. Oncol. (2002) 21:138a (Abstract).
37. CUNNINGHAM D, DE GRAMONT A, SCHEITHAUER W et al.: Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:126a (Abstract).
38. VAN CUTSEM E, KARASEK P, OETTLE H et al.: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol. (2002) 21:130a (Abstract).
39. LIU M, BRYANT MS, CHEN J, LEE S et al.: Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. (1998) 58:4947-4956.
40. ADJEI AA, ERLICHMAN C, DAVIS JN et al.: A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. (2000) 60:1871-1877.
41. ESKENS FA, AWADA A, CUTLER DL et al.: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J. Clin. Oncol. (2001) 19:1167-1175.
42. SHARMA S, KEMENY N, KELSEN DP et al.: A Phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann. Oncol. (2002) 13:1067-1071.
43. LIPTON A, READY N, BUKOWSKI RM et al.: Phase I study of continuous oral lonafarnib plus weekly paclitaxel for advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:92a (Abstract).
44. PIERSON AS, HOLDEN SN, BASCHE M et al.: A Phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) sarasar (lonafarnib, SCH66336), cisplatin(C) and gemcitabine (G) in patients (pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:92a (Abstract).
45. SUN J, BLASKOVICH MA, KNOWLES D et al.: Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of Farnesyltransferase and Geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol and gemcitabine. Cancer Res. (1999) 59:4919-4926.
46. SHI B, YAREMKO B, HAJIAN G et al.: The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother. Pharmacol. (2000) 46:387-393.
47. ROSE WC, LEE FYF, FAIRCHILD CR et al.: Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. (2001) 61:7507-7517.
48. ZHU AX, SUPKO JG, RYAN DR, CLARK JW, BUTKIEWICZ L, EDER JP: A Phase I clinical, pharmacokinetic and pharmacodynamic study of the farnesyltransferase inhibitor BMS-214662 given as a 24 hour continuous intravenous infusion once weekly × 3 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:92a (Abstract).
49. EVANS TL, FIDIAS P, SKARIN A et al.: A Phase II study of efficacy and tolerability of the farnesyl-protein transferase inhibitor L-778,123 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2002) 21:13b (Abstract).
50. HAHN SM, BERNHARD EJ, REGINA W et al.: A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin. Cancer Res. (2002) 8:1065-1072.
51. MCKENNA WG, MUSCHEL RJ, GUPTA AK, HAHN SM, BERNHARD EJ: Farnesyltransferase inhibitors as radiation sensitizers. Semin. Radiat. Oncol. (2002) 12:27-32.
52. BRITTEN CD, ROWINSKY EK, SOIGNET S et al.: A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin. Cancer Res. (2001) 7:3894-3903.
53. MOASSER MM, ROSEN N: The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. Breast Cancer Res. Treat. (2002) 73:135-144.
54. ADJEI AA, DAVIS JN, ERLICHMAN C, SVINGEN PA, KAUFMANN SH: Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res. (2000) 6:2318-2325.
55. SMITH V, ROWLANDS MG, BARRIE E, WORKMAN P, KELLAND LR: Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin. Cancer Res. (2002) 8:2002-2009.
56. GERMANN UA: P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur. J. Cancer (1996) 32A:927-944.